Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial.
Andreas RilligLars EckardtKatrin BorofAlan John CammHarry J G M CrijnsAndreas GoetteGuenter BreithardtMarc D LemoineAndreas MetznerLaura RottnerUlrich SchottenEik VettorazziKarl WegscheiderAntonia ZapfHein HeidbuchelStephan WillemsLarissa FabritzRenate B SchnabelChristina MagnussenPaulus F KirchhofPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2024)
Long-term therapy with flecainide or propafenone appeared to be safe in the EAST-AFNET 4 trial to deliver effective ERC therapy, including in selected patients with stable cardiovascular disease such as coronary artery disease and stable HF. Clinical Trial Registration ISRCTN04708680, NCT01288352, EudraCT2010-021258-20, www.easttrial.org.
Keyphrases
- clinical trial
- cardiovascular disease
- phase ii
- coronary artery disease
- phase iii
- study protocol
- open label
- randomized controlled trial
- atrial fibrillation
- type diabetes
- percutaneous coronary intervention
- heart failure
- heart rate
- mesenchymal stem cells
- double blind
- metabolic syndrome
- cardiovascular risk factors
- smoking cessation
- transcatheter aortic valve replacement